 | | Vol. 24.04 – 6 February, 2023 |
| |
|
|
| Researchers showed that controlling the precise level of stimulation during T cell activation to accommodate individual differences in the donor cells would dictate the functional attributes of CAR-T cell products.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| A signal peptide-optimized and extracellular vesicles-delivered guide RNA and CRISPR/CasRx system capable of rapidly inhibiting the expression of targeted genes with quick catabolism was developed.
[Advanced Science] |
|
|
|
| Results indicated that adverse outcomes for patients with diffuse large B cell lymphoma meant to receive CAR T could be predicted using a simplified cumulative illness rating scale-derived comorbidity index.
[Blood Advances] |
|
|
|
| Scientists generated anti-human leukocyte antigen G (HLA-G) CAR-T cells and provided evidence for their effects in epidermal growth factor receptor (EGFR)-overactive oral cancer.
[iScience] |
|
|
|
| Investigators assessed the role that different host animal models and anatomic implant locations played in vascularization and cardiomyocyte survival within engineered tissues.
[Scientific Reports] |
|
|
|
| TM4SF1, a potential biomarker in many tumors, was validated highly expressed in ovarian cancer. Scientists constructed a 3rd generation CAR-T agent targeting TM4SF1 to treat ovarian cancer.
[Immunology Letters] |
|
|
|
| Researchers developed a new medical drug candidate for acute myeloid leukemia, a CAR targeting interleukin-1 receptor accessory protein (IL-1RAP) expressed by leukemia stem cells.
[Current Research in Translational Medicine] |
|
|
|
| CAR-T cells overexpressing RUNX3 were safer than conventional CAR-T cells, while RUNX3 could also maintain the anti-tumor efficacy of CAR-T cells in vivo.
[Medical Oncology] |
|
|
|
| Investigators employed cell sheets engineered from clinical-grade human clonal bone marrow-derived mesenchymal stem cells and transplanted these onto intact renal capsule to evaluate their therapeutic ability in the rat ischemia reperfusion injury model.
[Tissue Engineering Part C-Methods] |
|
|
|
|
| Scientists discuss some recent developments in the field of breast cancer-specific immunotherapy using CAR-T.
[Advances in Cancer Biology – Metastasis] |
|
|
|
|
| Gracell Biotechnologies, Inc. announced that the US FDA has cleared Gracell’s Investigational New Drug (IND) application and the Company can proceed to initiate a Phase Ib/II clinical trial in the US of GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refractory multiple myeloma.
[Gracell Biotechnologies, Inc.] |
|
|
|
|
| February 21 – 23, 2023
London, England, United Kingdom |
|
|
|
|
|
| | Fred Hutchinson Cancer Center – Seattle, Washington, United States |
|
|
|
| | Lund University- Lund, Sweden |
|
|
|
| | Umeå University – Umeå, Sweden |
|
|
|
| | Dresden University of Technology – Dresden, Germany |
|
|
|
| | The Ottawa Hospital – Ottawa, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
